We are live on ! Find out more
CP

Caligan Partners Portfolio holdings

AUM $2.13B
1-Year Est. Return 758.65%
This Fund
S&P 500
This Quarter Est. Return
+57.99%
1 Year Est. Return
+758.65%
3 Year Est. Return
+2,628.41%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.13B
AUM Growth
+$623M
Cap. Flow
+$59.8M
Cap. Flow %
2.81%
Top 10 Hldgs %
80.89%
Holding
33
New
5
Increased
11
Reduced
3
Closed
5

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$45.1M
2
IMCR icon
Immunocore
IMCR
+$40.9M
3
VRDN icon
Viridian Therapeutics
VRDN
+$35.3M
4
AURA icon
Aura Biosciences
AURA
+$29.1M
5
AVTX icon
Avalo Therapeutics
AVTX
+$24.2M

Top Sells

Rank Stock Value
1
MLYS icon
Mineralys Therapeutics
MLYS
+$75.1M
2
SYRE icon
Spyre Therapeutics
SYRE
+$44.3M
3
XENE icon
Xenon Pharmaceuticals
XENE
+$27.9M
4
MBX
MBX Biosciences
MBX
+$22.7M
5
MAZE
Maze Therapeutics
MAZE
+$18.4M

Sector Composition

Rank Sector Weight
1 Healthcare 97.51%
2 Miscellaneous 2.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AGIO icon
26
CALL
Agios Pharmaceuticals
AGIO
$1.98B
$3.34M 0.16%
90,000
– –
ADMA icon
27
CALL
ADMA Biologics
ADMA
$2.11B
$2.51M 0.12%
300,000
– –
CLRB icon
28
Cellectar Biosciences
CLRB
$22M
$1.31M 0.06%
+469,998
New +$1.31M
CGON icon
29
CALL
CG Oncology
CGON
$6.54B
– –
-900,000
Closed -$60.9M
MLYS icon
30
Mineralys Therapeutics
MLYS
$2.45B
– –
-2,772,654
Closed -$75.1M
SYRE icon
31
Spyre Therapeutics
SYRE
$7.68B
– –
-878,127
Closed -$44.3M
XLO icon
32
Xilio Therapeutics
XLO
$60.7M
– –
-112,128
Closed -$943K
MAZE
33
Maze Therapeutics
MAZE
$1.44B
– –
-614,962
Closed -$18.4M
1
2

Similar funds

MWA
Midland Wealth Advisors Effingham, Illinois $2.13B AUM 17.72% 1-Year Est. Return
CWP
Cyndeo Wealth Partners St. Petersburg, Florida $2.12B AUM 24.61% 1-Year Est. Return
SP
Stairway Partners Chicago, Illinois $2.12B AUM 17.37% 1-Year Est. Return
OCM
Osterweis Capital Management San Francisco, California $2.12B AUM 32.36% 1-Year Est. Return
GC
Gobi Capital San Francisco, California $2.13B AUM 6.1% 1-Year Est. Return
BP
BBR Partners New York $2.13B AUM 21.87% 1-Year Est. Return
MSR
Main Street Research Lakeville, Connecticut $2.12B AUM 67.44% 1-Year Est. Return
NONA
Ninety One North America New York $2.13B AUM 9.16% 1-Year Est. Return

Caligan Partners's Q2 2026 Portfolio in Review

As of Q2 2026, Caligan Partners held 33 positions worth $2.13B, up 41% from $1.5B the previous quarter. Its ten largest holdings account for 81% of the portfolio.

Caligan Partners's Q2 2026 filing shows 5 new, 11 increased, 3 reduced and 5 closed positions. Its largest new stake was Immunocore: 1,381,317 shares worth $43.9M. The largest sale was Mineralys Therapeutics, an estimated $75.1M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 94% a quarter earlier, followed by Miscellaneous.

  • Caligan Partners's largest Q2 2026 buy was Immunocore: 1,381,317 shares worth $43.9M.
  • Caligan Partners added most to Revolution Medicines in Q2 2026, an estimated $45.1M increase.
  • Caligan Partners's biggest Q2 2026 reduction was Xenon Pharmaceuticals, cutting an estimated $27.9M.
  • Caligan Partners fully exited Mineralys Therapeutics in Q2 2026, selling an estimated $75.1M.
  • Caligan Partners's ten largest holdings make up 81% of its $2.13B portfolio in Q2 2026.
  • Caligan Partners opened 5 new positions and closed 5 in Q2 2026.
  • Caligan Partners's portfolio value rose 41% quarter-over-quarter to $2.13B.

Based on Caligan Partners's 13F filing for Q2 2026, filed 14 Aug 2026.